Devonian Health Group Inc. (GSD.V)

0.3200 0.0000 (0.00%) At close: 01:37PM EST

Devonian Health Group Inc.

360, rue des Entrepreneurs
Montmagny
Québec, QC G5V 4T1
Canada

https://groupedevonian.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Colette Laurin C.A., CPA	Interim CFO, Corp. Sec. & Corp. Controller	84k	N/A	N/A
Dr. Andre P. Boulet Ph.D.	Chief Scientific Officer	245.25k	N/A	1959
Mr. Pierre J. Montanaro	Pres, CEO & Director	N/A	N/A	N/A
Mr. Martin Moreau C.F.A., M.Sc.	Director	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products. The company was incorporated in 2015 and is headquartered in Québec, Canada.

Corporate Governance

Devonian Health Group Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.